Article
Brochure
Executive Resource
Ext. Publication
VideoMedtech Activity Signals Strong Growth in Q3 2024
Never miss a thing.
Sign up to receive our insights newsletter.
The medtech industry is experiencing a resurgence in investments, mergers and public offerings in 2024, reflecting market confidence and innovation momentum. According to J.P. Morgan’s Q3 2024 Medtech Licensing and Venture Report, venture capital activity, M&A transactions and IPOs have all surpassed prior-year benchmarks. Key highlights from the report indicate a strong trajectory for the sector heading into Q4.
Record-Breaking Venture Investments
Medtech venture activity through Q3 2024 reached $16.1 billion across 554 funding rounds. Notably, Q3 alone contributed $5.1 billion from 154 rounds — an increase of approximately $1 billion compared to Q3 2023. These investments underscore the market’s commitment to advancing medical devices, diagnostics, therapeutic digital health and commercial research tools.
M&A Momentum
Mergers and acquisitions continue to play a pivotal role in medtech’s growth story. Year-to-date, 195 acquisitions have been completed, totaling $47 billion. This marks a significant uptick in activity compared to 2023, which saw 128 deals worth $50.1 billion for the year.
Return of Medtech IPOs
After a two-year hiatus, medtech IPOs have made a comeback. Two companies successfully went public on NASDAQ and NYSE through Q3, raising a combined $500 million. This signals renewed investor confidence in the sector’s long-term growth and innovation potential.
Medtech companies’ continued success in the public markets is critical for the health and development of the broader life sciences ecosystem for two primary reasons, both of which lead to more investment in earlier-stage companies. First, IPOs release capital back to earlier-stage investors to be reinvested in other early-stage ventures — 2021 saw record funding levels, but much of the capital allocated for life sciences is tied up in these mature, illiquid companies on the precipice of an IPO. Second, successful IPOs amplify the FOMO (fear of missing out) for non-traditional life science investors, spurring crossover investments and increasing capital infusion. Regardless of the driver, new capital infusion is desperately needed and greatly hoped for by life science entrepreneurs and executives.
A Promising Outlook for Medtech
The medtech sector’s strong performance in venture funding, partnerships and public offerings highlights its resilience and adaptability in a dynamic health care landscape. The current market environment presents unparalleled opportunities for strategic partnerships and growth. As companies accelerate innovation and expand portfolios, they are paving the way for impactful advancements throughout the industry.
We are dedicated to helping medtech companies navigate the full spectrum of future opportunities. As the industry continues to innovate and expand, Weaver is here to provide leading solutions that meet the needs of today’s market. Contact us for comprehensive support.
©2024